Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Emixustat, is an inhibitor of the visual cycle isomerase with an IC50 value of 4.4 nM in vitro. a novel visual cycle modulator. 在相同实验条件下,摩尔浓度相同的化合物盐形式与游离态具有相同的生物活性,但盐形式 Emixustat hydrochloride 的水溶性和稳定性通常比游离态更好。
规格 | 价格/CNY | 货期 | 数量 | |
---|---|---|---|---|
2 mg | ¥ 889 | 5日内发货 | ||
5 mg | ¥ 1,660 | 5日内发货 | ||
25 mg | ¥ 6,910 | 6-8周 | ||
50 mg | ¥ 9,170 | 6-8周 | ||
100 mg | ¥ 14,500 | 6-8周 | ||
1 mL * 10 mM (in DMSO) | ¥ 1,320 | 5日内发货 |
Emixustat 的其他形式现货产品:
产品描述 | Emixustat, is an inhibitor of the visual cycle isomerase with an IC50 value of 4.4 nM in vitro. a novel visual cycle modulator. |
靶点活性 | Visual cycle isomerase:4.4 nM |
体外活性 | Emixustat strongly inhibits 11-cis-retinol production with an IC50 value of 232±3 nM.Emixustat potently inhibits isomerase activity in vitro (IC50=4.4 nM). Treatment of emixustat shows a concentration dependent reduction of 11-cis-ROL production . |
体内活性 | Pre-treatment with a single dose of emixustat (0.3 mg/kg) provids a 50%protective effect against light-induced photoreceptor cell loss, while higher doses (1-3 mg/kg) are nearly 100%effective.?In Abca4-/- mice, chronic (3 month) emixustat treatment markedly reduces lipofuscin autofluorescence and reduces A2E levels by 60%( ED50=0.47 mg/kg).?In the retinopathy of prematurity rodent model, treatment with emixustat during the period of ischemia and reperfusion injury produces a 30%reduction in retinal neovascularization (ED50=0.46mg/kg).Emixustat reduces the production of visual chromophore (11-cis retinal) in wild-type mice following a single oral dose (ED50=0.18mg/kg). In albino mice, emixustat is shown to be effective in preventing photoreceptor cell death caused by intense light exposure. |
别名 | ACU-4429 |
分子量 | 263.38 |
分子式 | C16H25NO2 |
CAS No. | 1141777-14-1 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 43 mg/mL (163.26 mM)
可选溶剂 | 浓度 体积 质量 | 1 mg | 5 mg | 10 mg | 25 mg |
DMSO | 1 mM | 3.7968 mL | 18.984 mL | 37.968 mL | 94.9199 mL |
5 mM | 0.7594 mL | 3.7968 mL | 7.5936 mL | 18.984 mL | |
10 mM | 0.3797 mL | 1.8984 mL | 3.7968 mL | 9.492 mL | |
20 mM | 0.1898 mL | 0.9492 mL | 1.8984 mL | 4.746 mL | |
50 mM | 0.0759 mL | 0.3797 mL | 0.7594 mL | 1.8984 mL | |
100 mM | 0.038 mL | 0.1898 mL | 0.3797 mL | 0.9492 mL |
对于不同动物的给药剂量换算,您也可以参考 更多...
请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法: 比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL,一共给药动物10 只,您使用的配方为5% DMSO+30% PEG300+5% Tween 80+60% ddH2O。那么您的工作液浓度为2 mg/mL。
母液配置方法:2 mg 药物溶于 50 μL DMSO (母液浓度为 40 mg/mL), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。
体内配方的制备方法:取 50 μL DMSO 主液,加入 300 μL PEG300, 混匀澄清,再加 50 μL Tween 80,混匀澄清,再加 600 μL ddH2O, 混匀澄清。
您可能有的问题的答案可以在抑制剂处理说明中找到,包括如何准备库存溶液,如何存储产品,以及基于细胞的分析和动物实验需要特别注意的问题。
Emixustat 1141777-14-1 Others ACU-4429 ACU4429 ACU 4429 Inhibitor inhibitor inhibit